Use of Follistatin-Like 1 (FSTL1) in Cardiometabolic Heart Failure
JP2025510782A5Pending Publication Date: 2026-06-15REGENCOR INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- REGENCOR INC
- Filing Date
- 2023-03-24
- Publication Date
- 2026-06-15
AI Technical Summary
⚠Technical Problem
Current treatments for cardiometabolic heart failure, such as diabetic cardiomyopathy, are inadequate in effectively reducing mortality, improving cardiac function, and preventing complications like coronary and cerebrovascular dysfunction.
⚗Method used
The use of non-glycosylated or hypoglycosylated follistatin-like 1 (FSTL1) polypeptides to contact cardiac tissue, which can be delivered systemically or locally to the heart, promoting repair and improving cardiac function.
🎯Benefits of technology
FSTL1 treatment has shown to reduce heart failure mortality, improve cardiac function, prevent left ventricular diastolic dysfunction, and enhance coronary and cerebrovascular function, thereby addressing the limitations of existing treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2023183933000001
Abstract
In particular, provided herein are compositions and kits comprising epicardium-derived paracrine factors such as follistatin-like 1 (FSTL1) for aiding in the treatment of cardiometabolic heart failure, and methods of using the same.A method for aiding in the treatment of cardiometabolic heart failure, comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.A method for treating cardiometabolic heart failure, comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.
Need to check novelty before this filing date? Find Prior Art